The success of this offering is critical for the company to fund its planned Phase 2b and Phase 2 trials and to uplist to Nasdaq. Monitor for pricing details and Nasdaq approval; if the offering closes as planned, it removes near-term going concern risk but significant dilution is expected.
Executive Summary
Eloxx Pharmaceuticals filed an amended S-1 registration statement to offer 1.5 million shares of common stock and pre-funded warrants to purchase up to 4 million shares of common stock at an assumed price of $10.00-$12.00 per share. The company plans to use the net proceeds of approximately $54.2 million to fund Phase 2b and Phase 2 trials of exaluren for Alport syndrome and ADPKD, respectively. The company currently trades on the OTC Pink Limited Market after Nasdaq delisting, has a going concern qualification, and the offering is contingent upon Nasdaq uplisting approval.
Key Financial Metrics
Key Facts
- Offering 1,500,000 shares of common stock and pre-funded warrants for up to 4,000,000 shares at an assumed price of $10.00-$12.00 per share
- Estimated net proceeds of approximately $54.2 million, based on the midpoint of the price range
- Proceeds allocated: $13.2M for exaluren Phase 2b Alport syndrome trial, $19.2M for exaluren Phase 2 ADPKD trial, remainder for working capital
- Company has a going concern qualification with $6.4 million cash as of March 31, 2026 and an accumulated deficit of $304.3 million
- Common stock quoted on OTC Pink; offering contingent on Nasdaq Capital Market listing approval
- Exaluren has received Orphan Drug Designation for Alport syndrome from the FDA
- Net losses of $5.995 million (2025), $3.143 million (2024), and $17.054 million (2023)
Financial Impact
Offering of up to $54.2 million in net proceeds; cash position of $6.4 million as of March 31, 2026; accumulated deficit of $304.3 million; net loss of $3.754 million in Q1 2026
Risk Factors
- Going concern risk if the offering does not close or is delayed
- Nasdaq uplisting approval is a condition of closing — no assurance of approval
- Significant shareholder dilution: pro forma shares outstanding increase from ~461k to ~1.96M (excluding pre-funded warrant exercise)
- Exaluren is the sole pipeline candidate; clinical trial failure would be catastrophic
- Material weakness in internal controls remains unremediated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-251655 |
| Document: d35071dex11.htm | 0001193125-26-251655 |
| Document: d35071dex1058.htm | 0001193125-26-251655 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | 8-K | $13.12 | awaiting T+20 | — | $13.17 (+0.38%) |
Sep 21, 2026 5w ago | EFFECT | $17.19 $12.50 | ▼ −27.28% | ▼ −26.38% | $13.17 (−23.39%) |
Sep 11, 2026 6w ago | S-1 | $16.30 | awaiting T+20 | — | $13.17 (−19.20%) |
Jun 9, 2026 19w ago | EFFECT | $11.01 $10.95 | ▼ −0.55% | ▼ −1.99% | $13.17 (+19.62%) |
Jun 4, 2026 20w ago | S-1/A | $6.20 | awaiting T+20 | — | $13.17 (+112.42%) |
Jun 1, 2026 20w ago | S-1/A | $1.51 | awaiting T+20 | — | $13.17 (+772.19%) |
Jun 1, 2026 21w ago | 8-K | $4.07 $13.88 | ▲ +241.03% | ▲ +242.33% | $13.17 (+223.59%) |
May 7, 2026 24w ago | S-1 | $1.43 | awaiting T+20 | — | $13.17 (+820.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers